Financial Results - The company ended Q1 2025 with cash totaling $4.6 million, an increase from $3.7 million as of December 31, 2024 [1] - Research and development expenses for Q1 2025 were $0.6 million, down from $1.6 million in Q1 2024, primarily due to decreased manufacturing and consulting costs [3] - General and administrative expenses for Q1 2025 were $1.6 million, a decrease from $2.8 million in Q1 2024, attributed to lower professional fees and share-based compensation costs [4] - The company reported a net loss of $2.1 million or $0.11 per diluted share for Q1 2025, compared to a net loss of $4.4 million or $0.28 per diluted share for Q1 2024 [5] Operational Highlights - The company received positive regulatory guidance from the European Medicines Agency (EMA) for the ibezapolstat Phase 3 clinical trial program, aligning with FDA feedback [2] - New publications in the Journal of Antimicrobial Agents and Chemotherapeutics highlighted non-clinical studies that differentiate ibezapolstat from other antibiotics for treating C. difficile infection [2] - A new patent for DNA polymerase IIIC inhibitors was granted by the Japanese Patent Office, expiring in December 2039, supporting the development of ACX-375C [2] - The company closed a registered direct offering and private placement, raising gross proceeds of $1.1 million in March 2025 [2] Product Development - Ibezapolstat is the lead antibiotic candidate advancing to international Phase 3 clinical trials for treating C. difficile infection [7] - Ibezapolstat is a novel, orally administered antibiotic with a Gram-Positive Selective Spectrum (GPSS®) that spares beneficial gut microbiota while targeting C. difficile [7] - The CDC has designated C. difficile as an urgent threat, emphasizing the need for new antibiotics [7] - The company’s R&D pipeline includes antibiotic candidates targeting Gram-positive bacteria, including MRSA and VRE [8]
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update